Kent T. Sato

Kent T. Sato

Auto-generated profile, based on publicly available information

Kent T. Sato

Department of Radiology, Section of Interventional Radiology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 676 North St. Clair, Suite 800, Chicago, IL 60611

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2009 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
RLRobert J. Lewandowski
Robert J. Lewandowski
ARAhsun Riaz
Ahsun Riaz
RRRobert K. Ryu
Robert K. Ryu
MMMary F. Mulcahy
Mary F. Mulcahy
KSKent T. Sato
Kent T. Sato
RSRiad Salem
Riad Salem

6 April 2016 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
SMSamdeep K. Mouli
Samdeep K. Mouli
RHRyan Hickey
Ryan Hickey
BTBartley Thornburg
Bartley Thornburg
KSKent T. Sato
Kent T. Sato
KDKush Desai
Kush Desai
RLRobert J. Lewandowski
Robert J. Lewandowski

1 October 2005 in Academic Radiology
Verified
Journal Article
Closed access
KSKent T. Sato
Kent T. Sato
ALAndrew C. Larson
Andrew C. Larson
TRThomas K. Rhee
Thomas K. Rhee
RSRiad A. Salem
Riad A. Salem
ANAlbert A. Nemcek
Albert A. Nemcek
ROReed A. Omary
Reed A. Omary

1 January 2008
Verified
Book Chapter
Closed access
SRStephen E. Rubesin
Stephen E. Rubesin
SASamuel Nathan Adler
Samuel Nathan Adler
SBStephen R. Baker
Stephen R. Baker
ABAparna Balachandran
Aparna Balachandran
DBDennis M. Balfe
Dennis M. Balfe
RZRivka Zissin
Rivka Zissin

15 September 2008
Verified
Book Chapter
Closed access
BABassel Atassi
Bassel Atassi
SISaad Ibrahim
Saad Ibrahim
PPPankit Parikh
Pankit Parikh
RRRobert K. Ryu
Robert K. Ryu
KSKent T. Sato
Kent T. Sato
RSRiad Salem
Riad Salem
90Yttrium (90Y) microspheres are 20- to 40-μ particles that emit beta radiation. Because the microspheres are delivered via the hepatic arterial route, the process can be considered “internal” rather than external radiation. The treatment algorithm is analogous to that followed with transarterial chemoembolization (TACE). Clinical history, physical examination, laboratory values and performance status are obtained. Patients are initially evaluated and staged using cross-sectional imaging techniques (computerized tomography [CT], magnetic resonance imaging [MRI], positron emission tomography [PET]). Once a patient is considered a possible candidate for therapy, evaluation using mesenteric angiography followed by treatment on a lobar basis is undertaken. Patients are followed clinically to assess toxicities and response prior to proceeding with treatment to the other lobe. A comprehensive review of the technical and methodological considerations in 90Y has been previously published (1–3). Two devices are commercially available. Thera- Sphere (glass) was approved in 1999 by the Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE) for the treatment of unresectable hepatocellular carcinoma (HCC) in patients with or without portal vein thrombosis who can have appropriately positioned hepatic arterial catheters (4). SIR-Spheres (resin) were granted full pre-marketing approval in 2002 by the FDA for the treatment of colorectal metastases in conjunction with intrahepatic floxuridine (FUDR) (5). Both devices have European approval for liver neoplasia and approvals in various Asian countries. OVERVIEW Patients with metastatic cancer to the liver from a colorectal primary tumor may be treated using surgical resection alone, providing a chance for long-term cure.